Abba Leffler

Dr. Abba E. Leffler, Ph.D., is a Senior Principal Scientist in the therapeutics group at Schrödinger, where he plays a leading role in early-stage drug discovery. Schrödinger is widely recognized for its physics-based computational platform, which allows scientists in biotechnology, pharmaceutical research, and materials science to model molecular behavior with remarkable precision. This approach significantly reduces reliance on traditional laboratory work, enabling researchers to explore chemical space more profoundly and more rapidly than would otherwise be possible.

​

Within this environment, Abba Leffler’s work stands at the intersection of chemistry, computation, and biology. He focuses on understanding the molecular mechanisms underlying disease and then applies computational tools, such as free-energy perturbation simulations and AI-driven modeling, to design promising therapeutic compounds. His expertise allows him to bridge the gap between complex biological systems and computationally generated insights, ultimately contributing to more efficient and accurate drug discovery.